The longevity drugs in clinical trials right now are not theoretical. They are real compounds, backed by billions of dollars from some of the wealthiest people on the planet, and several have already begun dosing human participants. In mid-December 2025, Retro Biosciences — funded with $180 million from OpenAI CEO Sam Altman — commenced its first-in-human trial in Australia, giving eight participants an oral drug called RTR242 that targets lysosomal function to combat Alzheimer’s disease. Weeks later, in January 2026, Life Biosciences received FDA approval for a Phase 1 clinical trial of ER-100, a gene therapy designed to reverse aging in the eye. Jeff Bezos has poured money into Altos Labs, which launched with $3 billion and reportedly began early human safety testing in August 2025 for neurodegenerative and immune-related aging disorders. These are not fringe experiments.
They represent a coordinated, well-funded assault on biological aging itself. For families navigating dementia care, this matters more than headlines about tech billionaires might suggest. Several of these trials directly target cognitive decline and Alzheimer’s disease. The senolytic combination of dasatinib and quercetin is in clinical trials for Alzheimer’s. The massive TAME trial aims to determine whether the cheap diabetes drug metformin can delay cognitive decline alongside cancer and cardiovascular disease. This article breaks down each major longevity drug currently in clinical trials, who is funding them, what the evidence actually shows so far, and what people concerned about brain health should realistically expect.
Table of Contents
- Which Longevity Drugs Are Billionaires Funding and Why?
- Epigenetic Reprogramming — The Most Ambitious Approach and Its Limitations
- Retro Biosciences and the Alzheimer’s Connection
- Metformin and Rapamycin — Cheap Drugs, Complicated Evidence
- Senolytics and the Problem of Scale
- The Role of AI in Accelerating Longevity Research
- What the Next Five Years Could Look Like for Longevity and Brain Health
- Conclusion
- Frequently Asked Questions
Which Longevity Drugs Are Billionaires Funding and Why?
The involvement of billionaires in longevity science is not philanthropy in the traditional sense. It is a bet — a calculated one — that aging can be treated as a disease rather than an inevitability. Sam Altman’s $180 million seed investment in Retro Biosciences is the clearest example. The company’s stated goal is to extend healthy human lifespan by ten years, and it is now raising $1 billion on an approximate $5 billion valuation. Altman is not donating to a cause. He is investing in a company whose value proposition depends on proving that cellular rejuvenation works in humans. Jeff Bezos backed Altos Labs with $3 billion in 2022, making it the most lavishly funded longevity startup in history.
Altos recruited top scientists from around the world and appointed Dr. Joan Mannick as chief medical officer to push research toward actual clinical programs. Brian Armstrong, the CEO of Coinbase, cofounded NewLimit and raised $130 million in Series B financing to pursue epigenetic reprogramming — the idea that you can reset a cell’s age without changing its identity. Meanwhile, the Hevolution Foundation out of Saudi Arabia has committed to spending up to $1 billion per year on aging research and agreed to fund one-third of the TAME metformin trial. What connects these funders is not ideology but a shared conviction that the science has reached a tipping point. The global anti-aging market generated over $85 billion in 2025 and is projected to reach roughly $120 billion by 2030. But the serious money is not chasing face creams and supplements. It is going into clinical trials that could fundamentally change how we treat age-related diseases, including dementia.
Epigenetic Reprogramming — The Most Ambitious Approach and Its Limitations
Epigenetic reprogramming is the headline technology in longevity science, and it carries both the greatest promise and the greatest uncertainty. The concept is straightforward in theory: as cells age, chemical tags on their DNA — the epigenome — accumulate errors that cause cells to lose their identity and function. Reprogramming aims to reset those tags, restoring youthful function without turning the cell back into an embryonic state, which would cause tumors. Life Biosciences, cofounded by Harvard professor David Sinclair, received FDA approval on January 30, 2026, for a Phase 1 clinical trial of ER-100, a gene therapy using partial epigenetic reprogramming to restore vision in patients with glaucoma and non-arteritic anterior ischemic optic neuropathy. First patients are expected to enroll within months, with results anticipated by the end of 2026 or early 2027. The limitation here is sobering. Life Biosciences has fewer than twenty employees.
This is not a massive pharmaceutical operation with decades of clinical infrastructure. The eye was chosen as a first target precisely because it is a contained organ — easier to monitor, less risk of systemic side effects. Translating epigenetic reprogramming from the eye to the brain, where it could theoretically reverse aspects of neurodegeneration, is a vastly more complex challenge. Altos Labs has the resources to attempt broader applications, and its early human safety testing reportedly targets neurodegenerative disorders among other aging conditions, but the company has released very little public data. However, if you are a caregiver or family member hoping that epigenetic reprogramming will soon be available for Alzheimer’s or other forms of dementia, it is important to understand the timeline honestly. Even in the best-case scenario, eye-focused results from ER-100 will not arrive until late 2026 or early 2027. Brain-targeted applications would require entirely separate trials, likely years further out. This technology is real, but it is early.
Retro Biosciences and the Alzheimer’s Connection
Of all the longevity companies currently running trials, Retro Biosciences has the most direct relevance to dementia care right now. Its first-in-human trial, which commenced in mid-December 2025 in Australia, is specifically testing RTR242 — a small-molecule therapy targeting lysosomal function — in the context of Alzheimer’s disease. The trial enrolled eight participants who took the drug orally, a significant detail because oral administration is far more practical for widespread use than gene therapy or infusions. Retro’s approach is rooted in autophagy, the process by which cells clean out damaged proteins and other debris. In Alzheimer’s disease, this cleanup system breaks down, allowing toxic proteins like amyloid-beta and tau to accumulate. By targeting lysosomal function, RTR242 aims to restore the cell’s ability to clear this waste.
In August 2025, Retro and OpenAI announced that their AI models had made cellular reprogramming fifty times more efficient, suggesting that artificial intelligence is accelerating not just the discovery of longevity targets but the optimization of therapies. The company’s broader mission — extending healthy human lifespan by ten years — sounds grandiose, but its near-term strategy is pragmatic. Starting with Alzheimer’s gives Retro a defined patient population, established clinical endpoints, and a regulatory pathway that the FDA already understands. If RTR242 shows safety and early efficacy signals, it could move into larger trials relatively quickly. That said, eight participants is a tiny cohort, and first-in-human trials are designed to test safety, not prove the drug works. Real efficacy data is still years away.
Metformin and Rapamycin — Cheap Drugs, Complicated Evidence
Two of the most discussed longevity drugs are not new compounds at all. Metformin has been prescribed for type 2 diabetes since the 1950s. Rapamycin, an mTOR inhibitor, has been used as an immunosuppressant since the 1990s. Both have shown suggestive anti-aging effects in animal studies and observational data, but the human evidence remains incomplete, and the tradeoffs are real. The TAME trial — Targeting Aging with Metformin — is the first FDA-approved anti-aging trial in history. Conceived by Dr. Nir Barzilai at Albert Einstein College of Medicine, it plans to track 3,000 elderly people over five years to determine whether metformin delays cardiovascular disease, cancer, cognitive decline, and mortality.
The trial’s estimated cost of $45 to $75 million proved difficult to raise precisely because metformin is a generic drug with no patent protection — no pharmaceutical company stands to profit from proving it works for aging. The Hevolution Foundation’s agreement to fund one-third of the cost helped push total funding to approximately $75 million, finally making the trial viable. Rapamycin, by contrast, has produced more ambiguous results. The PEARL trial, conducted by AgelessRx, followed 114 participants aged 50 to 85 over 48 weeks with weekly doses of 5 or 10 milligrams. The drug was well-tolerated and showed modest changes in biological aging biomarkers, but there was no clear clinical evidence that rapamycin extends human lifespan. Recent reviews have found no direct human evidence of life extension from rapamycin, despite promising animal data. For anyone considering rapamycin off-label — and many longevity enthusiasts already take it — this gap between animal studies and human results should give pause, particularly for older adults who may be more vulnerable to its immunosuppressive effects.
Senolytics and the Problem of Scale
Senolytic drugs, which selectively destroy senescent or “zombie” cells that accumulate with age and drive inflammation, represent one of the more intuitive approaches to treating aging. The combination of dasatinib (100 mg) and quercetin (1,250 mg) is the most studied senolytic regimen and is currently in multiple clinical trials for Alzheimer’s, cognitive decline, and mental health disorders. The dosing protocol — two consecutive days every two weeks over twelve weeks — is notably intermittent, reflecting the fact that senescent cells do not regenerate quickly after being cleared. A pilot study in older adults at risk for Alzheimer’s disease found that the dasatinib-quercetin combination was safe and feasible, with no serious adverse events reported. That is encouraging, but it is important to understand what “safe and feasible” means in clinical language: the drug did not harm people in a small trial.
It does not mean the drug prevented or treated Alzheimer’s. Large-scale efficacy data is still pending, and until those trials report results, the senolytic approach to cognitive decline remains a promising hypothesis rather than a proven therapy. The cautionary tale in this space is Unity Biotechnology, which was backed by Jeff Bezos among others. Despite encouraging Phase 2b results for its drug UBX1325 in diabetic macular edema, Unity shut down in September 2025. The closure was not because the science failed outright but because the path from promising results to commercial viability proved too uncertain. For patients and families, Unity’s fate is a reminder that even well-funded, scientifically credible longevity companies can collapse before their drugs reach the market.
The Role of AI in Accelerating Longevity Research
Artificial intelligence is not just a parallel technology trend happening alongside longevity research — it is becoming integral to it. When Retro Biosciences and OpenAI announced in August 2025 that their AI models had made cellular reprogramming fifty times more efficient, it signaled a shift in how longevity drugs are discovered and optimized. Traditional drug development can take a decade or more from target identification to clinical trial.
AI is compressing that timeline by predicting which molecular modifications will be most effective, simulating cellular responses, and identifying patient populations most likely to benefit. This acceleration matters for brain health specifically because neurodegenerative diseases are notoriously difficult to study. The brain is hard to biopsy, Alzheimer’s develops over decades before symptoms appear, and clinical trial endpoints are difficult to measure. If AI can identify biomarkers that predict Alzheimer’s progression more accurately, or model how a drug like RTR242 interacts with aging neurons, it could reduce the time between early trials and treatments that actually reach patients.
What the Next Five Years Could Look Like for Longevity and Brain Health
The next five years will determine whether the current wave of longevity funding produces real therapies or joins the long list of scientific ambitions that ran ahead of the evidence. Several concrete milestones are already on the calendar. Life Biosciences expects results from its ER-100 gene therapy trial by late 2026 or early 2027. The TAME metformin trial, now fully funded at approximately $75 million, will generate data over its five-year follow-up period that could reshape how medicine thinks about aging as a treatable condition.
Retro Biosciences’ RTR242 trial will produce initial safety data that determines whether lysosomal-targeted therapy advances to larger Alzheimer’s studies. For families dealing with dementia today, none of these timelines offer immediate relief. But the scale of investment — billions of dollars from people who have built careers on identifying transformative technologies — suggests that this is not a passing fad. The more realistic expectation is that the first longevity therapies to reach patients will target specific age-related diseases like Alzheimer’s and macular degeneration, rather than aging itself. That narrower focus, while less dramatic than the promise of reversing aging, is precisely what could produce treatments that matter for brain health within this decade.
Conclusion
The longevity drugs now entering clinical trials represent the most serious, well-funded effort in history to treat aging as a medical condition. From Retro Biosciences’ Alzheimer’s-focused RTR242 trial to Life Biosciences’ epigenetic reprogramming gene therapy to the long-awaited TAME metformin trial, real compounds are being tested in real people. Billionaire funding from Sam Altman, Jeff Bezos, Brian Armstrong, and the Hevolution Foundation has pushed these programs past the theoretical stage and into human studies. The senolytic combination of dasatinib and quercetin and the mTOR inhibitor rapamycin are also generating clinical data, though results so far are preliminary.
None of these drugs are available as longevity treatments today, and anyone who tells you otherwise is selling something. The closure of Unity Biotechnology despite promising results is a reminder that the path from clinical trial to approved therapy is long and uncertain. But for the first time, multiple well-designed human trials are specifically asking whether aging — and its most devastating consequence, cognitive decline — can be meaningfully slowed or reversed. Families affected by dementia should follow these trials with cautious attention, discuss emerging evidence with their physicians, and resist the urge to self-medicate with unproven regimens. The science is moving fast, but it has not arrived yet.
Frequently Asked Questions
Are any longevity drugs currently approved by the FDA for anti-aging use?
No. While several longevity drugs are in clinical trials, none have been approved by the FDA specifically to treat aging. Metformin is approved for diabetes, rapamycin for immunosuppression, and dasatinib for certain cancers, but their use for longevity is investigational. The TAME trial is the first FDA-approved trial specifically designed to test a drug against aging itself.
Can rapamycin prevent Alzheimer’s disease?
There is no direct human evidence that rapamycin prevents Alzheimer’s or extends human lifespan. The PEARL trial showed the drug was well-tolerated in 114 participants over 48 weeks, with modest changes in biological aging biomarkers, but no clear clinical benefit for longevity was demonstrated. Animal studies are more promising, but those results have not translated to proven human outcomes.
What is Retro Biosciences’ RTR242 and how does it relate to dementia?
RTR242 is a small-molecule oral therapy that targets lysosomal function to enhance autophagy — the cellular cleanup process that removes toxic protein buildup. Retro Biosciences began its first-in-human trial in Australia in mid-December 2025, specifically in the context of Alzheimer’s disease. The initial trial included eight participants, and it is designed to establish safety before larger efficacy trials can begin.
Why has the TAME metformin trial taken so long to fund?
Metformin is a generic drug that costs pennies per pill, which means no pharmaceutical company can profit from proving it works for aging. The estimated trial cost of $45 to $75 million had to come from philanthropic and government sources. The Hevolution Foundation ultimately agreed to fund one-third of the cost, helping the trial reach approximately $75 million in total funding.
What happened to Unity Biotechnology?
Unity Biotechnology, which was backed by investors including Jeff Bezos, shut down in September 2025 despite encouraging Phase 2b results for its drug UBX1325 in diabetic macular edema. The closure highlights the financial and regulatory challenges that longevity companies face even when their science shows promise.
Is the dasatinib and quercetin senolytic combination safe?
In clinical trials to date, the combination of dasatinib (100 mg) and quercetin (1,250 mg) given on two consecutive days every two weeks over twelve weeks has not produced serious adverse events. A pilot study in older adults at risk for Alzheimer’s confirmed the regimen was safe and feasible. However, large-scale efficacy data is still pending, and self-administering these drugs without medical supervision is not recommended.
